Trial Profile
A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Bupivacaine TTS (Bupivacaine Patch) in Patients With Chronic Low Back Pain.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Jun 2022
Price :
$35
*
At a glance
- Drugs Bupivacaine (Primary)
- Indications Back pain
- Focus Therapeutic Use
- Sponsors Pfizer
- 11 Apr 2011 Primary endpoint 'Pain-intensity' has not been met.
- 03 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 28 Jan 2011 Planned End Date changed from 1 Jan 2011 to 1 Feb 2011 as reported by ClinicalTrials.gov.